[Pubmed] A Fatal Case of Immune Checkpoint Inhibitor-Mediated Myasthenia Gravis, Myositis, and Cardiomyopathy Overlap Sy
Posté : 23 juil. 2024 12:00
Cancer Rep (Hoboken). 2024 Jul;7(7):e2140. doi: 10.1002/cnr2.2140.
ABSTRACT
BACKGROUND: Immune checkpoint inhibitors (ICIs) have led to improved outcomes for many cancer types. However, their use can also precipitate immune-related adverse events (irAEs) that can affect any organ system. While irAEs are often mild, they rarely affect multiple organ systems concurrently and can be fatal.
CASE: We report a fatal case of myasthenia gravis, myositis, and cardiotoxicity overlap syndrome precipitated by the ICI pembrolizumab along with a brief review of available literature.
CONCLUSION: Early recognition of high grade irAEs and prompt intervention is essential. Despite the poor prognosis of these overlap syndromes, current recommendations offer little guidance for severe cases and warrant a call for increased awareness and expansion of available therapeutics.
PMID:39041627 | DOI:10.1002/cnr2.2140
Source: https://pubmed.ncbi.nlm.nih.gov/3904162 ... t9+e462414